Key Highlights:
- Zydus Lifesciences launched Revahale (revefenacin), India’s first once-daily nebulized long-acting muscarinic antagonist (LAMA) for maintenance treatment of COPD, offering a new option for patients who require nebulized therapy.
- Revahale provides 24-hour sustained bronchodilation with one daily dose and is compatible with standard jet nebulizers. Its delivery approach reduces reliance on inhaler technique and inspiratory effort, supporting elderly patients and those with severe respiratory impairment.
- Clinical studies have shown significant, sustained lung-function improvements in patients with moderate to very severe COPD, with a favorable safety profile. The lung-selective therapy is designed to maximize airway bronchodilation while limiting systemic exposure.
Implications:
Revahale gives Indian COPD patients—especially older adults and those with severe breathing problems—a simpler, once‑daily nebulized option that doesn’t depend on strong inhaler technique, which can improve day‑to‑day symptom control and adherence. By offering sustained 24‑hour bronchodilation with standard jet nebulizers, it can reduce reliance on multiple daily doses or rescue inhalers and may shift prescribing toward more consistent maintenance therapy for patients who struggle with handheld devices.
Source: Zydus
